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INTRODUCTION 
Post-partum haemorrhage (PPH) and 
complications related to unsafe abortion are 
direct causes of maternal death in low- and 
middle-income countries; women, their 
families, and their communities all suffer as a 
result.  
 
In Senegal, actions to eradicate this problem 
have made significant advances in recent 
years. However, there is much left to do -- 
Senegal has not achieved Millennium 
Development Goal V, which called for the 
reduction of its maternal mortality ratio from 
392 to 127 deaths per 100,000 births by 2015. 
 
In pursuit this goal, Marie Stopes International 
(MSI), and the Population Council conducted a 
study on the knowledge and practice of 
misoprostol provision among pharmacy 
workers, as part of the “Strengthening 
Evidence for Programming on Unintended 
Pregnancy” (STEP UP) research program.  
 
This study is helping to guide strategies for 
expanding provision and proper delivery in 
pharmacies of misoprostol, a drug which is 
highly effective and acceptable for treating 
PPH and post-abortion complications. 
Misoprostol is included on the List of Essential 
Medicines of the WHO and of Senegal.   
  
STEP UP generates 
policy-relevant research 
to promote an evidence-
based approach for 
improving access to  
family planning and  
safe abortion.  
 
We work in Bangladesh, 
northern India, Ghana, 
Kenya, and Senegal. 
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BRIEF 
METHODOLOGY 
A survey was conducted among 110 
pharmacy owners, managers, or 
employees in September 2013 to assess 
the knowledge, attitudes and practice on:  
1) Availability of misoprostol; 
2) Knowledge of misoprostol;  
3) Reported misoprostol provision 
practices. 
 
Fieldwork was conducted in September 
2013.  
SUMMARY 
•   Pharmacies are key service delivery points for many women in Senegal. 
•   Currently, the majority of pharmacy workers do not have the knowledge to 
safely provide misoprostol to clients or health providers. 
•   Pharmacy workers’ knowledge of misoprostol needs to be strengthened. 
•   Further, the supply chain in Senegal needs to be strengthened to ensure 
access to all essential medications, including misoprostol. 
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RESULTS 
Knowledge of Misoprostol 
Respondents were generally under-informed of the many 
uses of misoprostol.  
 The majority (75%) knew the product can be used to 
treat gastric ulcers but only 13% were aware it can be 
used for PAC.  
 Knowledge of the drug’s use in preventing and treating 
PPH was also low (1% and 4% respectively).  
 Other gynaecological uses, such as cervical ripening 
(3%) and treatment of intrauterine foetal deaths (1%) 
were not well known either.  
This lack of knowledge suggests that the full range of 
uses for misoprostol are not well-understood by pharmacy 
workers in Senegal. Education is needed to take 
advantage of the potential reduction in maternal mortality 
and morbidity that the product can deliver. 
 
Another gap in knowledge related to side effects of the 
product.  
 Only 14% cited dizziness and 13% bleeding as side 
effects.  
 Almost half of the respondents (47%) stated that they 
were unaware of the existence of any side effects of 
misoprostol.  
Without this knowledge, pharmacy workers cannot 
appropriately counsel clients, raising potential health risks.  
 
Furthermore, few respondents were aware of the proper 
dosages of misoprostol for specific conditions:  
 38% of pharmacy workers reported knowing the 
correct dosage for misoprostol as a treatment for 
gastric ulcers. Of these, only 83% were able to 
correctly identify the proper dosage of 800 mcg.  
 14% of respondents reported that they knew the 
proper dosage for PAC. Yet, only 4% of these 
respondents correctly stated a dosage of between 400 
and 600 mcg.  
 No respondents reported knowing the correct dosage 
for the prevention and treatment of PPH.  
These results are concerning because without proper 
dosing, both the efficacy and the safety of misoprostol 
may be jeopardized. 
 
Storage is also an important factor in drug efficacy. 
Generally, respondents had partial understanding of 
storage requirements. While 84% of them knew that 
misoprostol should be kept away from heat, only 28% 
were aware that it must also be kept away from humidity. 
The lack of knowledge about misoprostol may be explained 
in part by the sources of information about the drug. Almost 
half (45%) of respondents reported that they self-trained on 
the uses of the product through literature, brochures, etc. 
Others received information through medical delegates (22%) 
and colleagues (20%). Only 10% of respondents received 
information during university training. Other information 
sources included doctors, clients, television, and the internet.  
 
Recognizing their lack of knowledge about the medication, 
85% of respondents desired further support and training on 
misoprostol. Many stated that they needed information about 
all aspects of the product (58%). More specific requests for 
information where about uses (37%), side effects (30%), 
complications (30%), and dosage (28%). Worryingly, even 
though respondents were not confident in their knowledge, 
they reported providing information to a range of providers, 
including midwives (75%), gynaecologists (42%), nurses 
(33%), and general practitioners (17%). This suggests the 
potential for diffusion of misinformation among medical 
professionals, and ultimately increased risk for patients. 
 
 
 
DGU: Duodenal or gastric ulcers  IUFD: Intrauterine fetal death  
NSAID-IPU: NSAID-induced peptic ulcers 
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Figure 1: Knowledge of misoprostol uses 
and registration
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The full potential of misoprostol has not yet 
been realised in Senegal. With increased 
pharmacy worker education on the drug, 
important progress could rapidly be made 
in the reduction of maternal mortality     
and morbidity. 
   
Provision of Misoprostol 
Twenty-seven (27) respondents reported selling 
misoprostol in their pharmacy (34% of the sample). 
However, 48% of those who were not selling the product 
did express the desire to do so.  
 
The majority of sales were for the treatment of gastric 
ulcers, reported by 63% of carriers of misoprostol. An 
average of 58 tablets was sold per month per pharmacy 
for all indications. Pharmacy workers who reported that 
they do not sell misoprostol were asked to explain why. 
The main reasons are presented in Figure 2 (right).  
 
The three brands of misoprostol available on the 
Senegalese market at the time of the study were: 
Arthrotec, Cytotec and Misoclear.  
 Arthrotec was the most widely sold (in 56% of 
pharmacies that sold misoprostol). Arthrotec is a 
combination medicine with diclofenac that is registered 
for the treatment of gastric ulcers.  
 Cytotec, also used to treat gastric ulcers, was available 
at 41% of pharmacies.   
 And, finally, Misoclear, which has been registered for 
additional gynaecological uses such as PAC and PPH, 
was available at 19% of pharmacies.  
 
Respondents reported that they decided on the types of 
misoprostol sold in their pharmacy based on what they 
know about the product’s efficacy and availability in the 
supply chain. It will only be possible for misoprostol to 
contribute to a reduction in the maternal mortality ratio if 
there is increased knowledge of misoprostol’s indications 
and increased availability of the product. 
 
A fifth (22%) of pharmacy workers reported that they had 
experienced clients asking for the medication without a 
prescription, but only one reported selling it in this 
situation.  
 
The majority (78%) of respondents believed that 
customers can afford the price of misoprostol, which is 9 
USD per box for Arthrotec, 27 USD per box for Cytotec 
and 4 USD per box for Misoclear.  
 
The majority of sales were for the treatment of gastric 
ulcers, reported by 63% of carriers of misoprostol. An 
average of 58 tablets was sold per month per pharmacy 
for all indications.  
 
 
 
 
 
DISCUSSION 
The pharmacy worker’s role is vital for the health of the 
general population. As a contact point for the public, it 
is important that pharmacy workers have a good 
understanding and a proper supply of misoprostol.  
 
A number of conclusions and recommendations can be 
drawn from this study. They can be grouped under the 
following categories: 
 
Increased communication: 
Even though the majority of pharmacy workers were 
aware of the use of misoprostol for gastric and 
duodenal ulcers, few knew of its gynecological 
applications. This suggests that the national approval 
of Misoclear for gynecological uses in 2011 has yet to 
be widely disseminated. To facilitate quicker diffusion 
of new policies and regulations, it is recommended that 
communication within the supply chain be 
strengthened, starting at the Pharmacy and Medicine 
Division of the Ministry of Health (MoH). This includes 
the dissemination of the List of Essential Medicines by 
the MoH, which will clarify the uses of misoprostol and 
has the potential to help de-stigmatize it. 
 
Increased education: 
The study revealed a general lack of knowledge 
regarding the proper dosage of misoprostol for all 
treatments. Additionally, almost half of respondents 
were unable to name any side effects at all. This is a 
potential risk for consumers.  Many respondents 
expressed the need for further training on misoprostol 
and its usages, especially for gynecological purposes. 
It is recommended that training sessions for 
pharmaceutical personnel be implemented. 
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Increased availability of misoprostol in pharmacies: 
Despite willingness to provide misoprostol, a low 
percentage of pharmacy workers reported stocking 
misoprostol at the time of the study due to low demand 
and stock outs.  Low demand for misoprostol may 
reflect low numbers of prescriptions by health 
providers. Further studies among health providers are 
needed to explore how to increase prescription and use 
of misoprostol in the fight against maternal morbidity 
and mortality.  
  
Pharmacists and distributors have a key role to play in 
ensuring there is no stock out of the product, by 
responding effectively and continuously to demand. 
Recently, steps taken in Senegal to strengthen the 
supply chain have been successful in preventing stock 
outs of contraceptives. Similar efforts are required to 
strengthen the supply chain for other important 
medications for reducing maternal mortality such as 
misoprostol.  
 
CONCLUSION 
The Senegalese government has made significant 
efforts in the fight against maternal morbidity and 
mortality. However, at the time of the study, misoprostol 
was not yet widely available in the public health 
system.  
 
Amplified communication about the product can 
contribute to an increase in demand from providers in 
all sectors. However, as demand for the product 
increases, the supply chain must be strengthened to 
respond effectively and avoid shortages.  
 
The Ministry of Health has committed to working with 
the Order and Syndicate of Pharmacies to ensure the 
availability of essential medicines, including 
misoprostol, and to train pharmacy workers to allow 
them to sell misoprostol safely for gynaecological 
purposes. Misoprostol has a significant role to play in 
reducing maternal mortality, but it must be made more 
available at the points where people most commonly 
access the health system, including pharmacies. 
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KEY RECOMMENDATIONS 
 
 Strengthen communication between the 
Pharmacy and Medicine Division of the 
Ministry of Health and drug suppliers to 
facilitate quicker diffusion of new laws 
and regulations. 
 Disseminate widely the List of Essential 
Medicines to health providers and 
pharmacy workers to increase 
knowledge, and decrease 
misconceptions, about priority drugs 
and their indications in the Senegalese 
context. 
 Hold training sessions for 
pharmaceutical personnel to increase 
knowledge of medications on the List of 
Essential Medicines, in particular 
misoprostol.  
 Increase the availability of misoprostol 
among drug distributors and in 
pharmacies to respond effectively to 
demand and avoid shortages. 
 Conduct further studies about 
knowledge and uses of misoprostol 
among health providers, as they are 
able to prescribe misoprostol, to 
explore ways to increase prescription 
and uses. 
